Pharmacogenomics in cardiovascular diseases
- PMID: 12077721
- DOI: 10.1053/pcad.2002.123467
Pharmacogenomics in cardiovascular diseases
Abstract
Considerable heterogeneity exists in the way individuals respond to medications, in terms of both efficacy and safety. Inherited differences in the absorption, metabolism, excretion, and target for drug therapy have important effects on drug efficacy and safety. Pharmacogenomics aims to discover new therapeutic targets and understand genetic polymorphisms that determine the safety and efficacy of medications. The goal of pharmaco-genomics is customization of drug therapy with administration of a medication in an optimum dose that will be safe and effective with reduction in morbidity and mortality.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Similar articles
-
Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.Am J Cardiovasc Drugs. 2002;2(5):287-96. doi: 10.2165/00129784-200202050-00001. Am J Cardiovasc Drugs. 2002. PMID: 14727958 Review.
-
Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.Expert Opin Pharmacother. 2005 Dec;6(15):2565-76. doi: 10.1517/14656566.6.15.2565. Expert Opin Pharmacother. 2005. PMID: 16316297 Review.
-
[Pharmacogenomics of cardiovascular pharmacology].Nihon Yakurigaku Zasshi. 2006 Sep;128(3):130-2. doi: 10.1254/fpj.128.130. Nihon Yakurigaku Zasshi. 2006. PMID: 16971774 Review. Japanese. No abstract available.
-
New collaborations make pharmacogenomics a SNP.Mol Med Today. 1999 Jul;5(7):280. doi: 10.1016/s1357-4310(99)01503-8. Mol Med Today. 1999. PMID: 10377514 No abstract available.
-
Clinical applications of pharmacogenomics.Rev Med Chil. 2017 Apr;145(4):483-500. doi: 10.4067/S0034-98872017000400009. Rev Med Chil. 2017. PMID: 28748996 Review.
Cited by
-
Personalized medicine: Time for one-person trials.Nature. 2015 Apr 30;520(7549):609-11. doi: 10.1038/520609a. Nature. 2015. PMID: 25925459 No abstract available.
-
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events.J Atheroscler Thromb. 2025 Mar 1;32(3):265-280. doi: 10.5551/jat.RV22031. Epub 2024 Dec 28. J Atheroscler Thromb. 2025. PMID: 39756980 Free PMC article. Review.
-
Economics and quality of care for patients with acute coronary syndromes: the impending crisis.Clin Cardiol. 2002 Nov;25(11 Suppl 1):I9-15. doi: 10.1002/clc.4960251304. Clin Cardiol. 2002. PMID: 12428814 Free PMC article. Review.
-
Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Curr Cardiol Rep. 2024 Jul;26(7):675-680. doi: 10.1007/s11886-024-02071-0. Epub 2024 May 28. Curr Cardiol Rep. 2024. PMID: 38806977 Review.
-
Phenomics and Robust Multiomics Data for Cardiovascular Disease Subtyping.Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1111-1123. doi: 10.1161/ATVBAHA.122.318892. Epub 2023 May 25. Arterioscler Thromb Vasc Biol. 2023. PMID: 37226730 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources